(Total Views: 402)
Posted On: 05/17/2021 5:39:34 PM
Post# of 36568
Re: homerbedloe #29317
Good point about trial design.
Keep in mind CYDY's studies and protocol were designed at the beginning of covid when little was known about the mechanism of action and the endpoints chosen were best guesses at the time. Turns out they chose unwisely but hindsight is hindsight. Plus CYDY chose not to modify the endpoints as some others did, like remdemsivir when it became obvious to GILD the endpoints wouldn't be met. The other big mistake they made was declining an offer to do a combo study with GILD using leronlimab and remdesivir. That would have given them instant credibility and expertise vs going solo.
A lot more is known now and as far as vaccines are concerned the path is very well lit for NGIO thanks to JNJ, PFE etc.
Keep in mind CYDY's studies and protocol were designed at the beginning of covid when little was known about the mechanism of action and the endpoints chosen were best guesses at the time. Turns out they chose unwisely but hindsight is hindsight. Plus CYDY chose not to modify the endpoints as some others did, like remdemsivir when it became obvious to GILD the endpoints wouldn't be met. The other big mistake they made was declining an offer to do a combo study with GILD using leronlimab and remdesivir. That would have given them instant credibility and expertise vs going solo.
A lot more is known now and as far as vaccines are concerned the path is very well lit for NGIO thanks to JNJ, PFE etc.
(1)
(0)
